Aspirin for the primary prevention of skin cancer: A meta-analysis

Zhu,Yun; Cheng,Yang; Luo,Rong‑Cheng; Li,Ai‑Min

doi:10.3892/ol.2015.2853

Aspirin for the primary prevention of skin cancer: A meta-analysis

Authors:
- Yun Zhu
- Yang Cheng
- Rong‑Cheng Luo
- Ai‑Min Li
View Affiliations

Affiliations: Cancer Center, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China, Digestive Department of Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China
Published online on: January 7, 2015 https://doi.org/10.3892/ol.2015.2853
Pages: 1073-1080
Copyright: © Zhu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Skin cancer is one of the most common cancers worldwide. There are three major skin cancer types: basal cell carcinoma, squamous cell carcinoma and malignant melanoma.General risk factors for skin cancer include fair skin, a history of tanning and sunburn, family history of skin cancer, exposure to ultraviolet rays and a large number of moles. The incidence of skin cancer has increased in the USA in recent years. Aspirin intake is associated with chemoprotection against the development of a number of types of cancer. However, whether aspirin intake can reduce the risk of development of skin cancer is unclear. The present meta‑analysis of available human studies is aimed at evaluating the association between aspirin exposure and the risk of skin cancer. All available human observational studies on aspirin intake for the primary prevention of skin cancer were identified by searching MEDLINE (Pubmed), BIOSIS, EMBASE, Cochrane Library and China National Knowledge Infrastructure prior to March 2013. The heterogeneity and publication bias of all studies were evaluated using Cochran's Q and I2 statistics, followed by a random‑effect model where applicable. The pooled data were analyzed by odds ratios (ORs) and 95% confidence intervals (CIs). A total of eight case‑control and five prospective cohort studies from 11 publications were selected for this analysis. There was no evidence of publication bias in these studies. Statistical analyses of the pooled data demonstrated that that a daily dose of 50-400 mg aspirin was significantly associated with a reduced risk of skin cancers (OR, 0.94; 95% CI, 0.90‑0.99; P=0.02). Stratification analysis indicated that the continual intake of low dose aspirin (≤150 mg) reduced the risk of developing skin cancer (OR, 0.95; CI, 0.90‑0.99; P=0.15) and that aspirin intake was significantly associated with a reduced risk of non‑melanoma skin cancers (OR, 0.97; CI, 0.95‑0.99; P=0.22). Overall, these findings indicated that aspirin intake was associated with a reduced risk of developing skin cancer. However, more well‑designed randomized controlled trials to measure the effects of aspirin intake are required to confirm this.

View Figures

View References

1	D’Orazio J, Jarrett S, Amaro-Ortiz A and Scott T: UV radiation and the skin. Int J Mol Sci. 14:12222–12248. 2013. View Article : Google Scholar : PubMed/NCBI
2	Marks R: An overview of skin cancers. Incidence and causation. Cancer. 75:607–612. 1995. View Article : Google Scholar : PubMed/NCBI
3	Chen ST, Geller AC and Tsao H: Update on the Epidemiology of Melanoma. Curr Dermatol Rep. 2:24–34. 2013. View Article : Google Scholar : PubMed/NCBI
4	MacKie RM, Hauschild A and Eggermont AM: Epidemiology of invasive cutaneous melanoma. Ann Oncol. 20(Suppl 6): vi1–vi7. 2009. View Article : Google Scholar : PubMed/NCBI
5	Saladi RN and Persaud AN: The causes of skin cancer: a comprehensive review. Drugs Today (Barc). 41:37–53. 2005. View Article : Google Scholar
6	Council on Environmental Health, Section on Dermatology. Balk SJ: Ultraviolet radiation: a hazard to children and adolescents. Pediatrics. 127:588–597. 2011. View Article : Google Scholar : PubMed/NCBI
7	Kornek T and Augustin M: Skin cancer prevention. J Dtsch Dermatol Ges. 11:283–296; quiz 297–298. 2013.PubMed/NCBI
8	Buckman SY, Gresham A, Hale P, et al: COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer. Carcinogenesis. 19:723–729. 1998. View Article : Google Scholar : PubMed/NCBI
9	Fosslien E: Molecular pathology of cyclooxygenase-2 in neoplasia. Ann Clin Lab Sci. 30:3–21. 2000.PubMed/NCBI
10	Denkert C, Köbel M, Berger S, et al: Expression of cyclooxygenase 2 in human malignant melanoma. Cancer Res. 61:303–308. 2001.PubMed/NCBI
11	Nijsten T, Colpaert CG, Vermeulen PB, et al: Cyclooxygenase-2 expression and angiogenesis in squamous cell carcinoma of the skin and its precursors: a paired immunohistochemical study of 35 cases. Br J Dermatol. 151:837–845. 2004. View Article : Google Scholar : PubMed/NCBI
12	Rao CV and Reddy BS: NSAIDs and chemoprevention. Curr Cancer Drug Targets. 4:29–42. 2004. View Article : Google Scholar : PubMed/NCBI
13	Harris RE, Beebe-Donk J, Doss H and Burr Doss D: Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review). Oncol Rep. 13:559–583. 2005.PubMed/NCBI
14	Silva MT, Galvao TF, Zimmerman IR, Pereira MG and Lopes LC: Non-aspirin non-steroidal anti-inflammatory drugs for the primary chemoprevention of non-gastrointestinal cancer: summary of evidence. Curr Pharm Des. 18:4047–4070. 2012. View Article : Google Scholar : PubMed/NCBI
15	Sneader W: The discovery of aspirin: a reappraisal. BMJ. 321:1591–1594. 2000. View Article : Google Scholar : PubMed/NCBI
16	Asgari MM, Chren MM, Warton EM, Friedman GD and White E: Association between nonsteroidal anti-inflammatory drug use and cutaneous squamous cell carcinoma. Arch Dermatol. 146:388–395. 2010. View Article : Google Scholar : PubMed/NCBI
17	Asgari MM, Maruti SS and White E: A large cohort study of nonsteroidal anti-inflammatory drug use and melanoma incidence. J Natl Cancer Inst. 100:967–971. 2008. View Article : Google Scholar : PubMed/NCBI
18	Cahoon EK, Rajaraman P, Alexander BH, Doody MM, Linet MS and Freedman DM: Use of nonsteroidal anti-inflammatory drugs and risk of basal cell carcinoma in the United States Radiologic Technologists study. Int J Cancer. 130:2939–2948. 2012. View Article : Google Scholar
19	Curiel-Lewandrowski C, Nijsten T, Gomez ML, Hollestein LM, Atkins MB and Stern RS: Long-term use of nonsteroidal anti-inflammatory drugs decreases the risk of cutaneous melanoma: results of a United States case-control study. J Invest Dermatol. 131:1460–1468. 2011. View Article : Google Scholar : PubMed/NCBI
20	Gamba CA, Swetter SM, Stefanick ML, et al: Aspirin is associated with lower melanoma risk among postmenopausal Caucasian women: the Women’s Health Initiative. Cancer. 119:1562–1569. 2013. View Article : Google Scholar : PubMed/NCBI
21	Jacobs EJ, Thun MJ, Bain EB, Rodriguez C, Henley SJ and Calle EE: A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst. 99:608–615. 2007. View Article : Google Scholar : PubMed/NCBI
22	Jeter JM, Bonner JD, Johnson TM and Gruber SB: Nonsteroidal anti-inflammatory drugs and risk of melanoma. J Skin Cancer. 2011:5985712011. View Article : Google Scholar : PubMed/NCBI
23	Jeter JM, Han J, Martinez ME, Alberts DS, Qureshi AA and Feskanich D: Non-steroidal anti-inflammatory drugs, acetaminophen, and risk of skin cancer in the Nurses’ Health Study. Cancer Causes Control. 23:1451–1461. 2012. View Article : Google Scholar : PubMed/NCBI
24	Johannesdottir SA, Chang ET, Mehnert F, Schmidt M, Olesen AB and Sørensen HT: Nonsteroidal anti-inflammatory drugs and the risk of skin cancer: a population-based case-control study. Cancer. 118:4768–4776. 2012. View Article : Google Scholar : PubMed/NCBI
25	Joosse A, Koomen ER, Casparie MK, Herings RM, Guchelaar HJ and Nijsten T: Non-steroidal anti-inflammatory drugs and melanoma risk: large Dutch population-based case-control study. J Invest Dermatol. 129:2620–2627. 2009. View Article : Google Scholar : PubMed/NCBI
26	Torti DC, Christensen BC, Storm CA, et al: Analgesic and nonsteroidal anti-inflammatory use in relation to nonmelanoma skin cancer: a population-based case-control study. J Am Acad Dermatol. 65:304–312. 2011. View Article : Google Scholar : PubMed/NCBI
27	Wells GA, Shea B, O’Connell D, et al: The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Department of Epidemiology and Community Medicine, University of Ottawa; Canada: http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm. Accessed October 12, 2007
28	Begg CB and Mazumdar M: Operating characteristics of a rank correlation test for publication bias. Biometrics. 50:1088–1101. 1994. View Article : Google Scholar : PubMed/NCBI
29	Egger M, Davey Smith G, Schneider M and Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ. 315:629–634. 1997. View Article : Google Scholar : PubMed/NCBI
30	Higgins JP, Thompson SG, Deeks JJ and Altman DG: Measuring inconsistency in meta-analyses. BMJ. 327:557–560. 2003. View Article : Google Scholar : PubMed/NCBI
31	DerSimonian R and Laird N: Meta-analysis in clinical trials. Control Clin Trials. 7:177–188. 1986. View Article : Google Scholar : PubMed/NCBI
32	Christenson LJ, Borrowman TA, Vachon CM, et al: Incidence of basal cell and squamous cell carcinomas in a population younger than 40 years. JAMA. 294:681–690. 2005. View Article : Google Scholar : PubMed/NCBI
33	An KP, Athar M, Tang X, et al: Cyclooxygenase-2 expression in murine and human nonmelanoma skin cancers: implications for therapeutic approaches. Photochem Photobiol. 76:73–80. 2002. View Article : Google Scholar : PubMed/NCBI
34	Asgari M, White E and Chren MM: Nonsteroidal anti-inflammatory drug use in the prevention and treatment of squamous cell carcinoma. Dermatol Surg. 30:1335–1342. 2004.PubMed/NCBI
35	Fürstenberger G, Marks F and Müller-Decker K: Cyclooxygenase-2 and skin carcinogenesis. Prog Exp Tumor Res. 37:72–89. 2003. View Article : Google Scholar : PubMed/NCBI
36	Cole BF, Logan RF, Halabi S, et al: Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst. 101:256–266. 2009. View Article : Google Scholar : PubMed/NCBI
37	Bardia A, Olson JE, Vachon CM, et al: Effect of aspirin and other NSAIDs on postmenopausal breast cancer incidence by hormone receptor status: results from a prospective cohort study. Breast Cancer Res Treat. 126:149–155. 2011. View Article : Google Scholar
38	Zhang X, Smith-Warner SA, Collins LC, Rosner B, Willett WC and Hankinson SE: Use of aspirin, other nonsteroidal anti-inflammatory drugs, and acetaminophen and postmenopausal breast cancer incidence. J Clin Oncol. 30:3468–3477. 2012. View Article : Google Scholar : PubMed/NCBI
39	Burn J, Gerdes AM, Macrae F, et al: CAPP2 Investigators: Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet. 378:2081–2087. 2011. View Article : Google Scholar : PubMed/NCBI